Abbott India Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹59,189 Cr
- Book Value
- ₹2,248
- Stock P/E
- 38.3
- Dividend Yield
- 1.89%
- ROE
- 34.4%
- ROCE
- 44.8%
- PEG Ratio
- 2.19
- EV/EBITDA
- 26.2
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Abbott India Ltd closed at ₹25,800.00 on 3 November 2026, down 0.1% on the day, 1.2% below its 50-day average, 15.8% below its 52-week high, with volume at 3.52× its 20-session average.
- RSI 14
- 47.7
- vs 50-day SMA
- -1.2%
- vs 200-day SMA
- -3.0%
- From 52-week high
- -15.8%
- Relative volume
- 3.52×
- 20-day return
- -1.2%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
What the exchange files show
NSE EOD ·Abbott India Ltd settled 60.1% of its traded volume as delivery on 3 November 2026, against a median of 55.1% across 109 sessions since 29 May 2026, above the 46.1% median for liquid NSE shares that day.
NSE assigns Abbott India Ltd a 20% daily price band and closed at neither limit in the 109 sessions it has carried that band here.
- Delivery, latest
- 60.1%
- Delivery, 109-session median
- 55.1%
- Delivery range
- 33.2–82.8%
- Daily price band
- 20%
- Close x volume, latest
- ₹48.9 cr
- Series
- EQ
Corporate actions
- 24 Jul 2026 — Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share
Prices, delivery and the price band come from NSE's published end-of-day files (sec_bhavdata_full and sec_list), covering 109 sessions from 29 May 2026. Surveillance status, disclosed deals and corporate actions come from separate NSE feeds on their own schedules and are not bounded by that window. Descriptive exchange data, not investment advice. What delivery percentage does and does not tell you →
Abbott India share price today
Abbott India (NSE: ABBOTINDIA) is what a pharma business looks like with the risk removed. No US FDA plants to trip over, no generic price wars, no leverage — just dominant Indian prescription brands: Thyronorm (thyroid, category-defining), Duphaston (gynaecology), Udiliv, Digene. Doctors prescribe by brand name; patients stay for years; price increases arrive annually.
The result: 44.8% ROCE, 34.4% ROE, zero debt, a 1.9% dividend yield from a payout the balance sheet never notices, and a 17.5% five-year profit CAGR on single-digit revenue growth — operating leverage in slow motion. At 38.3×, the tension is whether reliable branded-pharma compounding can outrun the drag of a premium starting multiple.
Brands that behave like annuities
Chronic-therapy brands are the closest thing pharma has to subscription revenue. Thyroid, gastro and women’s-health patients refill for decades, brand switching is medically discouraged, and the Abbott name carries doctor trust built over generations. The portfolio needs almost no capital — hence dividends and cash piling up — and the parent’s global pipeline provides steady in-licensing options.
Watch-items: price-control expansions under NLEM (the ceiling-price list), trade-generics competition nibbling at flagship molecules, single-digit volume growth in a maturing market, and the royalty/import bill to the parent.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹59,189 Cr |
| P/E (TTM) | 38.3 |
| EV/EBITDA | 26.2 |
| Operating margin | 27.3% |
| ROE / ROCE | 34.4% / 44.8% |
| Debt to equity | 0.04 |
| Sales CAGR (5y) | 10.0% |
| Profit CAGR (5y) | 17.5% |
| Promoter holding | 75.0% |
| EPS (TTM) | ₹727.1 |
Abbott India share price target 2026 to 2030
EPS base ₹727.1 (TTM). Bear: NLEM widens and growth stalls — 7% growth, multiple at 26×. Base: brands compound with annual pricing — 12% growth at 33×. Bull: new launches accelerate the portfolio — 15% growth at 42×.
From ₹27,825, the base case is ≈ +52% over four and a half years plus the 1.9% yield. The bear case is only −5% — this is what buying quality with a real yield does to downside math. The range below is where that math turns properly attractive.
Reasons to own Abbott India (at the right price)
- Zero-risk-profile pharma: no US FDA exposure, no generics knife-fight, no debt.
- Chronic brands with annuity refill economics — Thyronorm alone anchors the P&L.
- 45% ROCE and rising dividends from a capital-light model.
- MNC parent pipeline provides launches without R&D spend.
- 17.5% profit CAGR on 10% sales growth — margin expansion still running.
The risks: government price controls are the single biggest swing factor, growth is steady rather than fast, and 75% promoter holding means thin float and occasional violent moves.
What to weigh at the current price
Abbott remains a wonderful business, but a fair price depends on steady profit compounding offsetting a 38.3× starting multiple.
FAQ
What is the Abbott India share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.
Why does Abbott India trade at a premium to Indian pharma? Because it carries none of Indian pharma’s classic risks — no US plant inspections, no ANDA price erosion. Pure branded-domestic franchises earn annuity multiples.
What is NLEM risk? The National List of Essential Medicines caps prices of listed drugs. When a flagship molecule enters the list, its pricing power vanishes overnight — the recurring bear case for every branded player.
When are Abbott India’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.